NCLT Hyderabad sanctions demerger of Bharat Biotech, transferring two undertakings to newly incorporated Ellask Tracon and Ellacrity Infratech.
Demerger involves transfer of assets and liabilities with appointed date of 1 April 2025, approved via 1:1 share exchange ratio for shareholders.
Tribunal confirms all regulatory objections from RD, OL, and Income Tax department addressed via company undertakings and replies.
Scheme aims to create focused business units for real estate development and treasury/marketing operations from Bharat Biotech's diversified assets.